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Objective: Gonadotropin-releasing hormone (GnRH) receptor is found in the ovarian tissue, including
epithelial ovarian cancer (EOC), suggesting that GnRH agonists may have direct action on EOC.
Materials and methods: Ovarian clear cell cancer (ES-2) cells were treated with low-dose GnRH agonist
with/without low-dose paclitaxel (1 mM D-Lys6 with/without 0.5 mM or 1.0 mM paclitaxel). Growth and
behavior of ES-2 cells were evaluated.
Results: Use of either D-Lys6 or paclitaxel or a combination of the two did not affect the morphology and
growth pattern of ES-2 cells. However, ability of migration and invasion of ES-2 cells was signiﬁcantly
decreased in either use of D-Lys6 or paclitaxel and more apparent with the combination. Type I GnRH
receptor expression of ES-2 was not altered signiﬁcantly by the combination.
Conclusion: GnRH agonist might modify the ES-2 ovarian cancer cells, and its role might be independent,
additional or synergistic, suggesting the potential role of the use of GnRH agonist in the management of
clear cell type of the ovarian cancer. However, the results of this study were derived using ES-2 ovarian
cancer cells, and might not be valid in other cell types of ovarian cancers.
Copyright  2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Epithelial ovarian cancer (EOC) incidence ranks second among
all gynecological cancers; it is the fourth leading cause of cancer-
related deaths in the USA [1], and the 10th leading cause of
cancer-related deaths in Taiwan [2], where its incidence has been
increasing recently [3]. The symptoms or signs of EOC are indolentd Gynecology, Taipei Veterans
12, Taiwan.
g@ym.edu.tw (P.-H. Wang).
bstetrics & Gynecology. Publishedand nonspeciﬁc [4,5], which results in a delayed accurate diagnosis
and more than two-thirds of the patients are diagnosed in the
advanced stages (stages III and IV) [6e8].
The gold standard strategy in the management of EOC is a
combination of complete surgical staging surgery (optimal
debulking surgery is preferred) [9] and the recommended standard
therapy of platinum analogs and texanes [10e12]. This standard
strategy signiﬁcantly increased median overall survival to 3 years,
compared with the 1-year survival achieved in the era prior to the
use of platinum [12,13].
However, long-term follow-up in the Gynecologic Oncology
Group 111 study and European Canadian Intergroup study (OV.10)
demonstrated progression-free survival in only 18% of patients at 6by Elsevier Taiwan LLC. All rights reserved.
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EOC is present. Many strategies have been proposed [14e16] and
one extensively tested approach has been to add a third cytotoxic
drug, based on themechanisms of resistance that are different from
the platinum or taxane in vitro, and evidence of some degree of
nonecross-resistance in the clinical setting [11]. Unfortunately, it is
disappointing that there was no statistically signiﬁcant superiority
or clinically useful beneﬁt associated with the three drugs,
compared with the control arms receiving carboplatin and pacli-
taxel every 3 weeks for six or more cycles [12].
The pharmaceutical industry has moved away from developing
new cytotoxic agents and is now concentrating on targeted thera-
pies instead, with new product pipelines consisting almost exclu-
sively of targeted therapies [11]. Similarly, the cooperative groups
have moved wholeheartedly toward testing targeted therapies,
such as vascular endothelial growth factor inhibition in conjunction
with carboplatin and paclitaxel in women newly diagnosed with
ovarian cancer, and away from testing additional cytotoxic agents
in ﬁrst-line combinations [17,18]. Although the progression-free
survival seemed to be prolonged, no overall survival beneﬁts
were obtained [17,18], suggesting that it is unlikely that any single
approach will result in the curing of women with EOC.
It is muchmore likely that a curewill come about froma series of
small improvements resulting from differing approaches, including
newer, better cytotoxic agents. Among these, hormones might be
one of the attractive candidates, because there is much evidence to
support the hormonal contribution to cancer, either functioning as
an initiator or a promoter [19e25]. Gonadotropin releasing hor-
mone (GnRH) is a hypothalamic factor that mediates reproductive
competence [26e32]. By binding to speciﬁc receptors (GnRH-R)
present on the pituitary gonadotropes, GnRH regulates gonado-
tropin release and, consequently, steroid hormone secretion from
the gonads. However, GnRH and GnRH-R are found in many other
normal tissues, including the breast, ovary, endometrium, placenta,
and prostate [33]; interestingly in addition, GnRH-R has been
expressed in androgen-independent prostate carcinoma, breast,
ovary, and endometrial cancers [34e41], as well as in tumors that
are not classically considered hormone-related (e.g., melanoma).
Furthermore, the observation that the activation of GnRH-R reduces
cell proliferation andmetastatic behavior of breast cancer cell lines,
both in vitro and in vivo, indicates a possible additional and more
direct antitumor activity for these compounds [38]. All suggest a
clinical utility of the administration of GnRH agonist (that are more
stable than the native peptide) also in these tumors [42,43]. Based
on this rationale, we investigated the potential agents that might
involve the ovarian cancer behavior or growth in vitro.
Methods
Cell culture
A human ovarian carcinoma cell line (ES-2) was cultured and
maintained in McCoy’s 5A supplemented with 10% fetal bovine
serum (FBS) and 1% penicillinestreptomycin. These cells were
incubated at 37C in a humidiﬁed atmosphere of 5% CO2.
Thiazolyl blue assay
The thiazolyl blue (MTT) assay is quantitative colorimetric assay
for mammalian cell survival and proliferation [44e46]. ES-2 cells
were seeded at 5  103 in 35-mm plates in RPMI 1640 with 5%
charcoal-stripped/heat-inactivated FCS, grown for 24 hours, then
exposed to GnRH agonist (1 mM D-Lys6, Cetrotide, Serono, Geneva,
Switzerland), paclitaxel (0.5 mM or 1 mM; Bristol-Myers Squibb,
Princeton, NJ, USA), or a combination of D-Lys6 and paclitaxel. Themedium was renewed every other day. At the 1st day, 3rd day, and
5th day, 200 mL of 5 mg/mL MTT (Sigma-Aldrich, St Louis, MO, USA)
was added to each plate with 1 mL of medium for 4 hours at 37C.
After incubation, 2 mL of 0.04 N HCL in isopropanol was added into
each well. After several rounds of pipetting and 5 minutes of in-
cubation at room temperature, the absorbency was read at a test
wavelength of 570 nm. Subtract background absorbance was
measured at 690 nm. Results are expressed as the mean standard
deviation of six to eight replicates.
Cell-Matrigel adhesion assay
The 96-well microplates were precoated with 25 mg/well of
Matrigel basement membrane extract (Collaborative Biomedical
Products, Bedford, MA, USA) [46]. ES-2 cells (4  104) pretreated
with 1 mM D-Lys6 with/without 0.5 mM or 1.0 mM paclitaxel or not
pretreated (control) were seeded into the Matrigel precoated wells
and incubated for 30 minutes at 37C in a 5% CO2 incubator. The
cells were washed twice with PBS to gently remove unattached
cells; attached cells were ﬁxed with 3.7% formaldehyde for 30
minutes. Hoechst 33258 nuclear stain (Molecular Probes, Eugene,
OR, USA) and a ﬂuorescence microscope (DMIRB; Leica, Solms,
Germany) were used to measure the number of ﬁxed cells attached
to the Matrigel, which were counted in nine randomly selected
microscopic ﬁelds (400)/well. Independent experiments were
performed at least three times.
Migration assay
This assay was used to investigate the migratory abilities of tu-
mor cells exposed to GnRH agonist with/without antineoplastic
agents. The Transwell (Costar Corp.,Washington, DC, USA) consisted
of upper and lower chambers that were separated by Millipore
membranes with 8-mmpore sizes and a surface diameter of 6.5 mm
[46,47]. Cells able to move from the top surface of the Millipore
membranes to the undersurface of the membrane were considered
migratory. In brief, Es-2 cells (4  104) pretreated with 1 mMD-Lys6
with/without 0.5 mM or 1 mM paclitaxel were added to the upper
chamber with medium containing with 1 mM D-Lys6 with/without
0.5 mM or 1 mMpaclitaxel. After incubation at 37C for 24 hours, the
nonmigrating cells on the upper surface of the ﬁlter were scraped
off, and the migrating cells on the lower surface were ﬁxed, stained
withHoechst, and countedwith aﬂuorescencemicroscope as above.
Wound-healing assay
Cancer cellswere treatedwith1mMD-Lys6with/without0.5mMor
1.0 mMpaclitaxel for 24 hours. A cell-free gap of 500mmwas created
after removing the Culture-Insert (ibidi, Martinsried, Germany). The
cells that migrated into the wound area were calculated as follows:
500 mme (5e12-hour area 500mm)/0-hour area. Four independent
experiments were photographed and quantiﬁed under amicroscope.
Real-time quantitative reverse transcription-polymerase chain
reaction
A cell pellet was snap-frozen in liquid nitrogen until RNA
extraction [48e53]. Cell pellets were then powdered in liquid ni-
trogen. Brieﬂy, total RNA was extracted from a frozen cell pellet
sample using the StrataPrep total RNA Miniprep kit (Stratagene, La
Jolla, CA, USA), and treated with an RNase-free DNase I (Stratagene,
La Jolla, CA, USA), following the manufacturer’s instructions. First-
strand cDNA was obtained using SuperScript II RNase H reverse
transcriptase (Invitrogen, Carlsbad, CA, USA), according to the
manufacturer’s protocol, by incubating 1 mg of total RNAwith oligo-
Fig. 1. The cytotoxic effect of gonadotropin-releasing hormone (GnRH) agonist
(Lys ¼ D-Lys6), and antineoplastic agent (Ta ¼ paclitaxel) on ovarian cell line-ES-2. (A)
There was no signiﬁcant difference of survival of ES-2 cells between an individual
agent use and combination (1 mM D-Lys6 and 0.5 mM paclitaxel). (B) There was no
signiﬁcant difference of survival of ES-2 cells between an individual agent use and
combination (1 mM D-Lys6 and 1.0 mM paclitaxel).
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volume of 20 mL. For the relative quantiﬁcation based on the relative
expression of a given transcript versus an appropriate housekeeping
gene transcript [mitochondrial adenosine triphosphate synthase 6
(mATPsy6)], the threshold cycle (Ct) number at which the increase
in the signal associated with the exponential growth of PCR prod-
ucts was detected using LightCycler Relative Quantiﬁcation Soft-
ware version 3.3 andGraphPad Prism software (GraphPad Software,
San Diego, CA, USA), according to the manufacturer’s instructions,
with housekeeping gene of mATPsy6, and different-type sialyl-
transferases (STs), in each sample, including cancer and normal
tissues. The Ct is proportional to the initial number of target mole-
cules and is used in the quantitative analysis (the lower the Ct, the
higher the gene expression level). To determine the copy number/
proportional representation of the different STs in the studied tis-
sues,DCtwas calculated by subtracting the Ct of the ST from the Ct of
the housekeeping gene mATPsy6 (the smaller the DCt, the higher
the gene expression level). Real-time quantitative reverse
transcription-polymerase chain reaction (RTQ-PCR) was performed
on a Lightcycler (Roche Diagnostics, Mannheim, Germany) using
LightCyclereDNAMaster SYBR green I (for all the above-mentioned
STs) or the LightCyclereFastStart DNA Master Hybridization Probes
(for appropriate STs). Brieﬂy, ampliﬁcation (LightCyclereFastStart
DNAMaster SYBR green I) was carried out in a total volume of 20 mL
containing 0.3 mM of each primer, 2 mL of 1:10 diluted LightCycler
DNA Master SYBR Green I stock, 1.6 mL of 25 mMMgCl2, and 5 mL of
1:5 diluted cDNA. Ampliﬁcation (LightCyclerTMeFastStart DNA
Master Hybridization Probe kits)was carried out in a total volume of
20 mL containing 0.4 mMof each primer, 0.3 mMof each hybridization
probe, 1.6 mL of 25 mM MgCl2, and 5 mL of 1:5 diluted cDNA.
Expression of the mATPsy6 housekeeping genewas used in the PCR
reaction as an internal control. No primer-dimers were generated
during the applied 30, 40, and 50 RTQ-PCR ampliﬁcation cycles. At
the end of each PCR reaction, the samples was cooled to 40 C, and
held for 30 seconds. Control reactions for product identiﬁcation
consisted of: (1) calculating the Ct number and comparing that for
the given gene primers and mATPsy6; and (2) determining the
length of the PCR products (bp), which was performed after
completing the PCR reaction on the LightCycler system, and spin-
ning down the content of the glass capillaries in a microtube. A 5 mL
aliquot of each PCR product was visualized after agarose gel elec-
trophoresis and ethidium bromide staining.
Western blotting
The cells were plated at a density of 106 cells in 100-mm dishes
and grown under standard conditions. After 2 days, culture media
were changed to fetal calf serum (FCS)-free and phenol-red-free
medium for 72 hours. The ES-2 cells were incubated with 100 nM
bovine epidermal growth factor (EGF; Sigma-Aldrich) for 10 mi-
nutes with or without previous incubation (15 minutes) with 1 mM
D-Lys6 with/without 0.5 mM or 1.0 mM paclitaxel. After 4 hours, the
cells were detached with 1 mL of a solution containing 0.5 g trypsin
(Biochrom, Cambridge, UK) and 5 mmol EDTA in 1 L phosphate
buffered saline (PBS)/bovine serum albumin (BSA) and then lysed
using a lysis buffer containing 9.5 M urea, 2.0% NP-40, and 5.0% b-
mercaptoethanol. The cell lysates were electrophoresed on sodium
dodecyl sulfateepolyacrylamide gel electrophoresis (7.5%) under
reducing conditions and transferred to nitrocellulose. The nitro-
cellulose membranes were blocked in 3% BSA (Sigma-Aldrich) in
TBST (10 mM Tris, pH 8, 500 mM NaCl, 0.1% Tween 20) for 2 hours;
incubated with polyclonal rabbit anti-human type I GnRH-R (Cal-
biochem, Bad Soden, Germany) in a 1:1500 dilution in 1% BSA in
TBST for 1 hour; and then, following washings, incubated with
horseradish peroxidase-conjugated anti-rabbit IgG in an 1:1000dilution in 1% BSA in TBST (Amersham (now GE Healthcare),
Amersham, Buckinghamshire, UK) for 1 hour. After washing, spe-
ciﬁcally bound antibody was detected using Western Lightning
Chemiluminescence Reagent Plus (PerkinElmer, Santa Clara, CA,
USA). Capture and analysis of the images of the protein bands was
performed by using an imaging system equipped with a charge-
coupled device (CCD) camera (AlphaImager 2200; Alpha Innotech
Corporation, San Diego, CA, USA) and quantiﬁed by software
AlphaEase (Alpha Innotech Corporation) [54,55].
Statistical analysis
For data on cell invasion assay, statistical comparisons among
groups were performed with a nonparametric ManneWhitney U
test. A p value < 0.05 was considered signiﬁcant.
Results
Absence of cytotoxicity effect of GnRH-agonist on ES-2 cells
The survival of ES-2 cells seemed to show little inﬂuence after
the treatment either GnRH agonist alone (1 mM D-Lys6), and
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dimethyl sulfoxide (control), suggesting these treatments did not
have a cytotoxic effect on the ES-2 ovarian cancer cells (Fig. 1). In
the combination therapy with either 0.5 mM (Fig. 1A) or 1 mM
paclitaxel (Fig. 1B), the cytotoxic effect was also minimal, suggest-
ing the use of a low dose of paclitaxel, D-Lys6, or the combination
therapy did not affect the survival of ES-2 cells.Absence of morphology change of GnRH-agonist on ES-2 cells
The morphology of ES-2 cells did not show a signiﬁcant dif-
ference after treatment with either 1 mM D-Lys6, paclitaxel
(0.5 mM or 1 mM), or a combination of 1 mM D-Lys6 and either
0.5 mM or 1 mM paclitaxel compared with dimethyl sulfoxide
(control; Fig. 2), which agreed with the survival analysis of ES-2
cells after a low dose of paclitaxel, D-Lys6 or the combination
therapy shown in Fig. 1.The expression of GnRH-R of ES-2 after low-dose paclitaxel or
GnRH-agonist treatment
In the study of mRNA expression of type I GnRH-R of ES-2 cells,
mRNA expression was relatively similar between the control and
GnRH agonist, or low-dose paclitaxel treatment (Fig. 3). In
agreement with the results of the mRNA expression of the type I
GnRH-R after GnRH agonist alone (1 mM D-Lys6), or an extremely
low-dose of paclitaxel alone (0.5 mM or 1 mM paclitaxel) or com-
bination therapy, protein levels of GnRH-R also failed to show a
signiﬁcant difference between the control and treatment groups
(Fig. 4).Fig. 2. (A) The morphology change of ES-2 cells. There is little difference of morphology chan
0.5 mM paclitaxel). (B) The morphology change of ES-2 cells. There is little difference of morp
D-Lys6 and 1 mM paclitaxel).Migration and invasion of ES-2 was impaired after a combination of
low-dose paclitaxel and GnRH-agonist treatment
To study the effect of GnRH antagonist on ES-2 cells, the invasion
and migration ability was signiﬁcantly decreased when the ES-2
cells were treated with a combination of 0.5 mM or 1 mM paclitaxel
and 1 mM D-Lys6 (migration assay in Fig. 5A and cell-Matrigel
adhesion assay in Fig. 5B). The wound healing experiment also
supported that the combination of 0.5 mM and 1 mM paclitaxel and
1 mM D-Lys6 signiﬁcantly decreased the migration ability of ES-2
cells, comparedwith control or 1 mMD-Lys6 treatment alone (Fig. 6).Discussion
The main component of the advanced stage of EOC is wide-
spread peritoneal dissemination; despite the high prevalence and
importance of this phenomenon, the underlying mechanisms
remain largely uncharacterized [37]. The expression of GnRH-R in
EOC cells has been proposed and conﬁrmed for years [56e60]. In
addition, in the earlier study of the effects of GnRH agonist on
proliferation of an ovarian cancer cell line, 2774, the results showed
that the effect of GnRH agonist on ovarian cancer cell proliferation
was independent of gonadotropin and steroid, but involved a cell
cycle regulatory event [61]. In addition, a high incidence of
apoptosis was found in OVCAR-3 and SKOV-3 EOC cell lines treated
with GnRH agonist, suggesting that the antiproliferative effect of
GnRH agonist in EOC cells may be mainly attributed to cytostatic
activities resulting in the blocking of cell cycle progression in the
G0/G1 phase and minimally related to the induction of apoptosis
[62]. By contrast, the growth of the human EOC cell line OV-1063
was suppressed by a direct action when the tumors were treatedge of the ES-2 cells between the control and GnRH agonist treatment (1 mM D-Lys6 and
hology change of the ES-2 cells between the control and GnRH agonist treatment (1 mM
Fig. 3. The study of expression of gonadotropin releasing hormone (GnRH) receptor of
ovarian cell line ES2. There is no signiﬁcant difference of mRNA expression of GnRH
receptor after different treatment. (A) 1 mM D-Lys6 and 0.5 mM paclitaxel; (B) 1mM D-
Lys6 and 1mM paclitaxel. Lys ¼ D-Lys6; Ta ¼ paclitaxel.
Fig. 5. Migration and invasion assays of ES-2 cells. (A) Combination of gonadotropin
releasing hormone agonist (Lys ¼ D-Lys6) and antineoplastic agent (Ta ¼ paclitaxel)
reduced migration ability of ES-2 cells. (B) Combination of gonadotropin releasing
hormone agonist (Lys: D-Lys6) and antineoplastic agent (Ta: paclitaxel) reduced in-
vasion ability of ES-2 cells.
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mediated through the high-afﬁnity GnRH-Rs [37], which was
further supported by Kang et al [63], because the antiproliferative
effect of the GnRH agonist on human ovarian surface epithelial cells
was time- and dose-dependent, and this inhibition was also re-
ceptor mediated, as cotreatment of human ovarian surface
epithelial cells with antide abolished the growth inhibitory effectsFig. 4. The study of protein levels of gonadotropin releasing hormone (GnRH) receptor of
receptor after different treatment (A): 1 mM D-Lys6 and 0.5 mM paclitaxel; and (B) 1 mM D-of the GnRH agonist. Gründler et al [64] found that the binding of
GnRH agonist to the GnRH-R inhibits the mitogenic signal trans-
duction pathway (EGF-induced expression of the early response
gene c-fos) of the EGF receptor in ovarian cancer lines (EFO-21, EFO-
27, SK-OV-3), suggesting that the coupling of both signal trans-
duction systems mediates the antiproliferative effect of GnRH
agonist. However, an in vivo animal study did not show a signiﬁcantovarian cell line ES2. There is no signiﬁcant difference of protein expression of GnRH
Lys6 and 1 mM paclitaxel. Lys ¼ D-Lys6; Ta ¼ paclitaxel.
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GnRH agonist in the management of the clinical EOC patients is not
satisﬁed [66e68]. Although a discrepancy of the effects of GnRH
agonist on the ovarian cancer cell lines between the in vitro and the
in vivo studies is found, GnRH-R of these cells might play an
important role, because many studies have shown that the effect of
GnRH agonist on the cells might be mainly mediated through the
receptor [37,56e60,63e68]. Unfortunately, the use of GnRH agonist
might result in internalization of GnRH-R of the ovarian cancer cell
lines, with subsequent reduction of GnRH-R density, compared
with those without treatment by GnRH agonist (80% vs. 100%,
p < 0.001) [59]. In this study, we found little signiﬁcant difference
in mRNA and protein expression of type I GnRH-R of ES-2 cells after
the cotreatment of GnRH agonist and low-dose paclitaxel, sug-
gesting that this combination could maintain the GnRH-R expres-
sion of ES-2 cells, which might avoid the downregulation of GnRH-
R of ES-2 cells, and further avoid the declining therapeutic effect on
the ovarian cancer cell line after GnRH treatment.
In recent studies published by Cheung’s group [34,36,37,39], the
importance of GnRH-R of EOCwas highlighted, because the authors
identify the integrin receptors, in particular b1 integrin, in medi-
ating GnRH-induced cell adhesion to the peritoneal, and the nearly
total inhibition of adhesion by the inhibition of b1 integrin, coupled
with a similar inhibition of a2 and a5 integrins, suggesting that
binding involving collagen I may represent an important role
unique to peritoneal metastases by EOC [34]. In an agreement with
the above report, we also found that GnRH agonist signiﬁcantly
impaired the migration and invasion ability of ES-2 ovarian cancer
cells (Figs. 5 and 6). Consistent with beneﬁts of cotreatment of
GnRH agonist and low-dose paclitaxel in our study (maintenance
of GnRH-R after cotreatment of GnRH agonist and low-dosepaclitaxel), the migration ability of ES-2 cells was signiﬁcantly
inhibited by the cotreatment of GnRH agonist and low-dose pacli-
taxel (Figs. 5 and 6). These observations not only were consistent
with a previous study [34], but also further hinted the possibility of
additional or synergistic effects of cytotoxic agents, such as pacli-
taxel by GnRH agonist.
We conclude that cotreatment of GnRH agonist with extremely
low-dose paclitaxel might enhance the effect of each other on the
ES-2 ovarian clear cancer cell line, suggesting that GnRH agonist
could be considered in some ovarian cancers, especially for clear-
cell types of EOC, and this observation is worthy of further
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